Collection of Blood From Patients With Prostate Cancer

Objectives:

-To obtain blood samples from patients with prostate cancer for genotyping analyses.

Eligibility:

• All patients seen in the NCI prostate cancer clinic are eligible.

Design:

• Patients with a prior diagnosis of prostate cancer will be evaluated in the GMB Clinic, NCI.
• Blood samples will be collected after the participant signs the protocol consent form. In general, blood will be collected for genomic DNA one time for this study. Extra samples may be requested if the original sample was not enough. The additional sample can range from one to two tubes of blood (approximately 2-3 teaspoons total). Genomic DNA and white blood cells will each be extracted from these samples to be utilized for genotyping and establishment of individual cell lines.
• Genetic variance will be correlated with prostate cancer prognosis (i.e. time from diagnosis to death) and prognostic indicators (i.e. histological tumor grade).
• Blood samples for the extraction of cell-free DNA (cfDNA) and cell-free RNA (cfRNA) may be collected at multiple timepoints for future investigations
• Healthy controls will not be compared and no correlations will be made with prostate cancer susceptibility.

• INCLUSION CRITERIA:

Individuals 18 years of age and older are eligible.

Individuals with a diagnosis of prostate cancer are eligible.

Exclusion criteria

Children are not eligible.